Benzinga | Feb 23, 2021 04:06PM EST

Adamas Pharmaceuticals Q4 EPS $(0.64) Misses $(0.51) Estimate, Sales $21.00M Beat $20.96M Estimate

Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.51) by 25.49 percent. This is a 22.89 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $21.00 million which beat the analyst consensus estimate of $20.96 million by 0.19 percent. This is a 28.46 percent increase over sales of $16.35 million the same period last year.